Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171791 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
A Phase 1 study of CTCL, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04171791: Completed Phase 1 study of CTCL, sponsored by Yale University.
NCT04171791 is a Phase 1 study of CTCL that has completed, run by Yale University. The registered enrollment target is 4 participants, below the 76-participant average among 4 other CTCL trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04171791, a Phase 1 study of CTCL, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.
Primary Outcome
Safety and tolerability endpoints will be evaluated on the basis of body temperature.
Conditions Studied
Interventions
- DRUG ABT-199 (venetoclax)
Study Locations (1)
Connecticut
- Yale New Haven Hospital / Smilow Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 1 |
What the finished NCT04171791 record still lists
NCT04171791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 76-participant average among 4 other CTCL trials with a reported enrollment target (95% lower).
The record links to 1 condition, with CTCL appearing as the primary indexed condition, and to 1 intervention - of which ABT-199 (venetoclax) is the first listed.
NCT04171791 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04171791 about?
NCT04171791 is a clinical study titled "A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)". The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.
What is the current status of trial NCT04171791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-01-15. Estimated completion is 2021-06-22.
What conditions does trial NCT04171791 study?
This clinical trial studies the following conditions: CTCL.
What interventions are being tested in trial NCT04171791?
The interventions under investigation include: ABT-199 (venetoclax) (DRUG).
Who is sponsoring clinical trial NCT04171791?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04171791 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTCL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
StrataCTX® as a Steroid Sparing Device
RECRUITING · NA
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
-
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI